Your Yourlocation: Home > Effect of tiotropium bromide(136310-93-5) on acute exacerbation and airflow limitation in COPD patients

To evaluate the role of tiotropium bromide(136310-93-5) in acute exacerbation of COPD and its airflow limitation. METHODS: Patients with COPD were enrolled in the First People's Hospital of Guangzhou City. Patients who met the criteria were randomized into 18 g of tiotropium bromide(136310-93-5) or placebo once daily for 48 weeks. At the 6th, 12th, 24th, 36th and 48th week after the randomization (day 1), patients with acute exacerbation of COPD were enrolled in this study. Details such as acute exacerbation of hospitalization and concomitant medication. Results: A total of 173 COPD patients, 87 patients in the tiotropium treatment group and 86 patients in the placebo group were significantly (2.32 ± 1.36) times in the previous year, and the morning expiratory peak velocity (PEF (225.7 ± 94.3) L / min, and the average first-second forced expiratory volume (FEV1) was (1.36 ± 0.76) L. Tiotropium significantly delayed the first acute exacerbation of about 91 days, reducing the proportion of patients with acute exacerbations more than once by 17%; compared with the placebo group, the number of acute exacerbations decreased by 34% and the number of days 36%. From the first week of the study to the end, the mean PEF weeks in the tiotropium group was also significantly higher than in the placebo group. At the end of the study, tiotropium bromide(136310-93-5) increased the FEV1 trough (before treatment), maximum lung capacity (FVC), and deep inspiratory (IC) in patients compared with placebo. Conclusion: Tiotropium reduces the number of acute exacerbations in COPD during the study year and improves the airflow limitation.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved